Business Context and Reporting Period
Company: James Hardie Industries plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: January 22, 2019
Reporting Period: The filing serves as a cover document for the Q3FY19 Results Notification (Exhibit 99.1). The text provided does not contain the specific financial results for the quarter.
Key Financial Metrics
The provided filing text is a procedural cover sheet and does not contain specific financial data. The following metrics are not present in the source text:
- Revenue
- Profit
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing references an attached "Q3FY19 Results Notification" (Exhibit 99.1) which would contain these figures, but the content of that exhibit is not included in the input text.
Material Changes
The filing text does not provide data to compare current performance against prior periods. No material changes in financial position or operations are detailed in the provided content.
Guidance, Outlook, and Risks
Forward-Looking Statements: The document contains an extensive disclaimer regarding forward-looking statements. These include projections on future performance, capital expenditure projects, credit facility renewals, dividend payments, and share buy-backs.
Key Risks Identified:
- Asbestos Liability: Risks related to prior asbestos manufacturing, contributions to the Asbestos Injuries Compensation Fund (AICF), potential shortfalls in the fund, and currency exchange impacts on asbestos liabilities.
- Legal and Regulatory: Exposure to product liability, environmental, and consumer class action proceedings.
- Market Conditions: Dependence on US and Asia Pacific housing markets, new home construction levels, and consumer confidence.
- Operational: Supply and cost of raw materials, competition, and integration of the Fermacell business.
- Financial: Currency exchange risks and the ability to renew credit facilities on favorable terms.
Investor Verification Checklist
- Verify the specific financial results (Revenue, EBITDA, Net Income) in the attached Exhibit 99.1 (Q3FY19 Results Notification), as they are not in this text.
- Confirm the status and funding adequacy of the Asbestos Injuries Compensation Fund (AICF).
- Review management commentary on the integration of Fermacell and its impact on operations.
- Assess the current outlook for US and Asia Pacific housing markets as cited in the risk factors.
- Check for any updates on pending legal proceedings or warranty provisions mentioned in the risk section.